Pathophysiological basis for therapy Some degree of gastro-oesophageal reflux occurs in the normal population, particularly postprandially, and should be considered a benign physiological process. The proposed factors contributing to pathological gastro-oesophageal reflux include oesophageal sphincter incompetence,"5 26 motility abnormalities causing impaired clearance of refluxed material,6 " the aggressive nature of refluxed material,'6" '9 impaired oesophageal epithelium defence mechanisms," 303' impaired gastric emptying," and finally, the presence of a hiatus hernia (box 4).
The role of Hpylori infection in the pathophysiology of GORD is under evaluation, but evidence to date would suggest that the infection does not have a role," '4 and indeed eradication may precipitate symptoms.
As in all areas of medical practice, management strategies in GORD should address the pathophysiological abnormalities underlying the clinical presentation, where possible. Foods known to decrease lower oesophageal sphincter pressure, including chocolate, peppermint and foods rich in fat, should be avoided."-"8 Alcohol also adversely affects the lower oesophageal sphincter, and oesophageal peristalsis, and should thus be discouraged.'5 39 40 Cigarette smoking should be avoided as it has been shown to decrease lower oesophageal sphincter pressure and also has deleterious effects on salivary function and mucosal resistance. '5 In addition, many medications commonly used in the treatment of other medical conditions have been associated with altered lower oesophageal sphincter tone and should be avoided where possible. They include nitrates, theophyllines, oral contraceptives and calcium channel blockers, particularly nifedipine. Calcium channel blockers may also exacerbate reflux by adverse effects on acid clearance. '5 4" Despite the fact that acid hypersecretion is only seen in a minority of patients with GORD,4 43 arguably most progress in the management ofthis condition has resulted from the development of agents which alter the aggressive nature of the refluxed material, especially the antisecretory properties of both the H2-receptor antagonists and the proton pump inhibitors. Acid and pepsin are both damaging to the oesophageal epithelium, and the damage is greater with both together than with either one alone. In addition, the presence of bile salts contributes to the damage.44 However, disordered motility, particularly transient relaxation of the lower oesophageal sphincter, is believed to be a more important factor than acid hypersecretion in the pathogenesis of GORD. The use of available prokinetic agents is mainly based on their ability to modifying oesophageal function by increasing lower oesophageal sphincter pressure and the amplitude of oesophageal contractions. They also enhance gastric emptying.
Treatment of GORD in clinical practice
Therapy should be initiated by recommending changes in lifestyle where appropriate. Many patients will have 'self-medicated','6 45 with antacids prior to review so any further prescription will probably involve either a proton pump inhibitor, a H2-receptor antagonist or a prokinetic agent. Whatever management strategy is chosen, the aims/endpoints of treatment are the same (box 5). 48 Proton pump inhibitors produce more profound suppression of acid and consistently achieve initial healing rates of over 90%. 26 49 In clinical trials the proton pump inhibitors are repeatedly superior to H2-receptor antagonists in terms of initial symptom relief and mucosal healing.5"'6 A large percentage of patients who are resistant to therapy with H2-receptor antagonists can be healed with proton pump inhibitors. Very few studies have directly compared the efficacy of different proton pump inhibitors and to date no substantial difference has been detected in terms of overall symptom relief and mucosal healing.57-59 There is some evidence, however, that lansoprazole induces symptom relief more rapidly than omeprazole.5-9 Pantoprazole, one of the newer proton pump inhibitors, is reported to have a higher degree of pharmacokinetic precision and fewer potential drug interactions. Cisapride is the most commonly used prokinetic agent, and has been shown to be superior to placebo in several studies.60-' It has also been shown to be as effective as H2-receptor antagonists in producing symptom relief.6"6 It is potentially more effective when there is a nocturnal predominance of symptoms, and concurrent motility symptoms.26
TREATMENT STRATEGIES ON INITIAL PRESENTATION
Two main treatment strategies using the available agents have been advocatedthe 'step-up' approach and the 'step-down' approach.26 In the former strategy, management starts with life-style advice (box 6) and the withdrawal of medications which impair either lower oesophageal sphincter pressure, gastric emptying or mucosal resistance. Antacids are also prescribed at this stage, but many patients will have had a trial before presentation. If these initial steps are unsuccessful, treatment is increased with either a H2-receptor antagonist or a prokinetic agent. If symptoms still persist, proton pump inhibitors are advised. Factors in favour of this approach would be the avoidance of powerful acid suppression in a large proportion of patients with mild disease. It would also theoretically result in the minimal amount of expense to the healthcare system and seems appropriate for a primary care setting.
The 'step-down' approach involves a strategy of going directly to a 4-8 week course of profound acid suppression with an agent such as a proton pump inhibitor. It will often be the most appropriate approach for the patient with more severe symptoms and advanced endoscopy findings. It results in rapid symptom relief and healing of the mucosa. Treatment is later stepped down to either a H2-receptor antagonist or a prokinetic agent and lifestyle modifications are introduced. However, patients may be reluctant to give up the symptom relief they experienced with the proton pump inhibitor when the other agents are introduced. 'Single-agent' therapy, whereby the clinician relies upon the same agent for the treatment of all grades of oesophagitis, has also been proposed as a third potential strategy. However, such an approach cannot be recommended at this stage as the H2-receptor antagonists or the prokinetic agents are ineffective in up to 40% of patients when used alone, while proton pump inhibitors are more expensive and unnecessary in many patients with mild symptoms.
MAINTENANCE OF REMISSION
GORD is a chronic disease with the majority of patients having a relapse of symptoms on treatment withdrawal despite initial healing.67 68 Up to 20% of patients will develop complications relating to their disease." Maintenance therapy is thus an important issue and the minimal dose of drug capable of symptom relief and maintaining mucosal healing is considered the ideal for long-term treatment. The therapeutic options for maintaining remission include 'on demand' medical treatment, 'maintenance' medical treatment or antirefiux surgery. On-demand therapy implies the episodic use of pharmacological agents for symptomatic relapse. This is a reasonable approach for patients with mild or infrequent symnptoms and/or grade 1 refiux disease at endoscopy. Maintenance or continuous therapy is more likely to be necessary in patients with high-grade oesophagitis or complications such as strictures, ulceration or Barrett's mucosa. Factors which have been shown to predict a need for long-term therapy include the presence of severe symptoms, advanced endoscopic findings, oesophageal motility abnormalities, nocturnal symptoms and poor response to H2-receptor antagonists69 70 A number of agents have been used in maintenance therapy -the H2-receptor antagonists or the prokinetic agents used alone give remission rates of 60% at one year, while the figure for proton pump inhibitors is about 85%.26
All of these agents were recently compared in a 12-month follow-up study71 after initial healing with omeprazole. Patients received either cisapride alone, ranitidine alone, omeprazole alone, ranitidine plus cisapride, or omeprazole plus cisapride. Omeprazole, alone or in combination with cisapride, was more effective than any other regime. While the combination of a prokinetic agent and an antisecretory agent is theoretically appealing due to the multifactorial pathogenesis of GORD, the small benefits in maintaining remission evident in this study (80% vs 89%) would suggest that such an approach would not be cost-effective for all patients. While there is little doubt about the efficacy of the proton pump inhibitors, some have expressed reservations about their use in the long-term. Observations to date are satisfactory, however, and up to 1995 more than 200 million patients worldwide had been treated with either omeprazole, lansoprazole or pantoprazole without severe side-effects.72 Some concern has also been expressed regarding the potential problems surrounding the effects of proton-pump-inhibitor-induced hypergastrinaemia73-75 on enterochromaffin-like cells, particularly in young patients, but to date these concerns have not been of significance in clinical practice. The monitoring of serum gastrin levels and fundic enterochromaffin-like cells is not advised in clinical practice, even during long-term proton pump inhibition. 75 In addition to considering the effect of GORD on patients symptoms and quality of life, physicians are also expected to consider the cost-effectiveness of their treatment regimes. Harris 34 and, in general, the prevalence of the infection is similar to that in control populations. These results would suggest that H pylori probably does not have a role in the pathogenesis of GORD. However, it has recently been reported that patients with Hpylori infection requiring long-term proton pump inhibition for the treatment of GORD have an increased risk of developing atrophic gastritis, when compared to a group of patients who had undergone antireflux surgery.80 This could in turn result in an increased risk of gastric cancer development. The groups in this study were not age-matched, however, and the older age of the patients receiving drug therapy could in part explain these results. These initial findings certainly need further evaluation, but at this stage many groups would consider eradication of H pylori before commencing long-term proton pump inhibition. In addition, therapy with proton-pump inhibitors alters the distribution of H pylori in the stomach; the bacteria are usually most numerous in the antrum, but treatment with these agents increases the numbers in the fundus.83 This has implications for the diagnosis of Hpylori, as the sensitivity of diagnostic tests based on biopsies from the antrum alone would be less. In addition, there may well be pathological consequences with gastric ulcers and gastric cancers thought to be more common in patients with a pangastritis. On the other hand, there is some evidence to suggest that, in the absence of Hpylori infection, the proton pump inhibitors may not achieve sufficient inhibition of gastric acid output for the optimal treatment of GORD. The elevation of pH achieved by these agents is less marked when the organism is absent.8' 82 It is clear that the role of Hpylori in both the pathogenesis and treatment of GORD needs further evaluation. The European Helicobacterpylori Study Group recently considered it 'advisable' on the basis of 'supportive' evidence, that H pylori should be eradicated when GORD requires long-term treatment with proton pump inhibitors.84 85 
